Hints and tips:
...“I think this is a mistake and can easily backfire,” said Suerie Moon, co-director of the Global Health Centre at the Graduate Institute of International and Development Studies in Geneva....
...Sinopharm is developing a second Covid-19 vaccine while Sinovac and CanSino Biologics, two other Chinese pharmaceutical companies, are also working to manufacture a jab....
...The company added it would continue searching for “co-development opportunities with multinational pharmaceutical and biotech companies”....
...Samsung Bioepis, meanwhile, is awaiting European regulatory approval of its own Remicade copy, as well as one based on Enbrel, another arthritis drug co-marketed by Pfizer and Amgen....
...Samantha Westgate Chief Executive, Perfectus Biomed Dr Conor Mulrooney Chief Operating Officer, Phagenesis Dr Chris Torrance Chief Executive, PhoreMost Santoke Naal Managing Director, Pierre Fabre Ltd...
...Biotechnology: Samsung is targeting annual sales of Won1.8tn by 2020 from its development of biopharmaceutical drugs....
...Apart from Motesanib Diphosphate, the remaining molecules included in the partnership are biologics. Takeda has cash reserves of about Y1,700,000bn and could make further acquisitions....
International Edition